Correlation of clinical outcome after rituximab-based chemoimmunotherapy with the expression pattern of Bcl-2 family proteins. Immunohistochemical analysis of expression of Bcl-2 (A), Mcl-1 (B), and Bcl-xL (C) in tumor biopsies of 14 patients with indolent B-cell lymphomas and 21 patients with aggressive B-cell lymphomas. Patients were grouped according to histology and clinical course (relapse or continued remission after rituximab-based salvage therapy). Protein expression was quantified after the IRS scoring system, and individual scores (points) as well as mean scores () are given. (D) For patients with aggressive lymphomas, the expression of Mcl-1 and phosphorylated AKT^S473 (p-AKT) was analyzed in relation to clinical course (mean values + SD).